Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04NWI
|
||||
Former ID |
DNC008250
|
||||
Drug Name |
(R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C14H21N
|
||||
Canonical SMILES |
CC1CCCN1CCC2=CC=CC(=C2)C
|
||||
InChI |
1S/C14H21N/c1-12-5-3-7-14(11-12)8-10-15-9-4-6-13(15)2/h3,5,7,11,13H,4,6,8-10H2,1-2H3/t13-/m1/s1
|
||||
InChIKey |
PXZKWHANTMQGIH-CYBMUJFWSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H3 receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Reactome | Histamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. Epub 2007 Oct 24.In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.